Intratumoral genetic heterogeneity may impact disease outcome. Gold standard for dissecting clonal heterogeneity are single-cell analyses. Here, we present an efficient workflow based on an advanced Single-Cell Printer (SCP) device for the study of gene variants in single cancer cells. To allow for precise cell deposition into microwells the SCP was equipped with an automatic dispenser offset compensation, and the 384-microwell plates were electrostatically neutralized. The ejection efficiency was 99.7% for fluorescent beads (n = 2304) and 98.7% for human cells (U-2 OS or Kasumi-1 cancer cell line, acute myeloid leukemia [AML] patient; n = 150). Per fluorescence microscopy, 98.8% of beads were correctly delivered into the wells. A subset of single cells (n = 81) was subjected to whole genome amplification (WGA), which was successful in all cells. On empty droplets, a PCR on LINE1 retrotransposons yielded no product after WGA, verifying the absence of free-floating DNA in SCP-generated droplets. Representative gene variants identified in bulk specimens were sequenced in single-cell WGA DNA. In U-2 OS, 22 of 25 cells yielded results for both an SLC34A2 and TET2 mutation site, including cells harboring the SLC34A2 but not the TET2 mutation. In one cell, the TET2 mutation analysis was inconclusive due to allelic dropout, as assessed via polymorphisms located close to the mutation. Of Kasumi-1, 23 of 33 cells with data on both the KIT and TP53 mutation site harbored both mutations. In the AML patient, 21 of 23 cells were informative for a TP53 polymorphism; the identified alleles matched the loss of chromosome arm 17p. The advanced SCP allows efficient, precise and gentle isolation of individual cells for subsequent WGA and routine PCR/sequencing-based analyses of gene variants. This makes single-cell information readily accessible to a wide range of applications and can provide insights into clonal heterogeneity that were indeterminable solely by analyses of bulk specimens.
Citation: Riba J, Renz N, Niemöller C, Bleul S, Pfeifer D, Stosch JM, et al. (2016) Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell Printing. PLoS ONE 11(9): e0163455. https://doi.org/10.1371/journal.pone.0163455
Editor: Javier S. Castresana, University of Navarra, SPAIN
Received: June 21, 2016; Accepted: September 8, 2016; Published: September 22, 2016
Copyright: © 2016 Riba et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: The research was supported in part by the Research Committee of the University Freiburg, Germany [BEC1058/15 (to HB)], the German Cancer Aid [DKH 111210 (to HB), Max Eder grant DKH 110461 (to RC)], the EHA and ASH Translational Research Training in Hematology (to HB), the SUCCESS program of the Department of Medicine I, Medical Center - University of Freiburg, Freiburg, Germany (to HB). JR and SZ were supported by the European Union under FP-7 (SICTEC, grant agreement number: 257073). KHM was supported by an EHA Clinical Research Fellowship. The funders provided support in the form of salaries for authors [JR CN SB JMS SZ], funds for research materials, or training, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the ‘Author Contributions’ section.”
Competing interests: PK and RZ are founders and scientific advisory board members of the cytena GmbH, which develops single-cell analysis and handling solutions. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The remaining authors have declared that no competing interests exist.
Intratumoral clonal heterogeneity may impact treatment response to chemotherapy or targeted therapies and hence the outcome of cancer patients [1,2]. Information on gene mutations derived from next generation sequencing (NGS) of bulk cell populations has been increasingly used to gain insights into the clonal heterogeneity of malignancies. However, this bioinformatically inferred data may only give an approximation of the definite clonal architecture. Single-cell genotyping is necessary to verify the co-existence of mutations in a cell and to derive reliable information about the clonal architecture and evolution of a disease.
Genetic information on the single-cell level has become more accessible in the recent years. This led to several studies which revealed deeper insights into the clonal architecture and evolution of various types of solid cancers and leukemias, all of which highlighted the importance of single-cell analyses [3–10]. As we and others have shown for acute myeloid leukemia (AML), single-cell sequencing is particularly useful for verifying the clonal architecture concluded from NGS data and for resolving the clonal assignment of mutations when NGS provides ambiguous or complex clonal architectures [6–9].
Prerequisites for accurate single-cell analyses are the efficient isolation of cells from the bulk sample and their precise deposition into reaction vessels for downstream analyses. Various methods for single-cell isolation have been developed which are more or less suitable depending on the downstream application [11,12]. Among the most frequently used approaches is fluorescence-activated cell sorting (FACS) which allows for high throughput isolation of single cells . However, FACS does not provide a direct proof that truly a single cell was isolated; moreover, the integrity of the cells may be compromised by the shear forces inherent to the system. More recently, various microfluidic approaches have been introduced such as hydrodynamic cell trapping as utilized by Fluidigm´s C1 system . However, these are limited in their flexibility of applications due to a determined chip design. In addition to such automated methods, single cells can be also picked manually with high precision by a microscope-assisted device but only at limited numbers.
The Single-Cell Printer (SCP), that we developed and that was used in the present study, is capable of isolating and depositing single cells with high viability rates in a label-free and non-contact manner  and has been previously used for single-cell PCR on human B-cells . Here, we further improve the droplet placement of the SCP to facilitate precise cell deposition into the center of the wells of standard 384-microwell plates. Furthermore, we study gene mutations and polymorphisms in cancer cells using routine PCR and Sanger sequencing after whole genome amplification (WGA) in order to evaluate the co-occurrence of mutations in individual cells and the clonal genetic architecture.
Materials and Methods
Cell lines and patient sample
The osteosarcoma-derived cell line U-2 OS (LINTERNA™ U-2 OS) was received from Innoprot (No. P20116; Derio, Spain) and cultured in DMEM/F12-Ham medium plus 10% FBS, 1% penicillin/streptomycin and 10 μg/ml puromycin in a humidified 5% CO2 atmosphere; for harvesting, cells were trypsinized. The AML-derived cell line Kasumi-1 was received from the research group of Michael Lübbert (University of Freiburg) who obtained it from DSMZ (No. ACC 220; Braunschweig, Germany); the cells were cultured in RPMI medium plus 10% FBS and 1% penicillin/streptomycin in a humidified 5% CO2 atmosphere. Furthermore, peripheral blood mononuclear cells (PBMCs) of a patient with AML were used (metaphase karyotype: 90–91, XXYY, -2, -5, +13x2, add(17)(p11), -21x2[cp8], 46,XY; interphase fluorescence in situ hybridization (FISH): 90% of cells had 3 signals for 17p13). Written informed consent was obtained from the patient prior to sampling. Sampling and research were approved by the ethics committee of the University Freiburg on 13. June 2013 and under the reference no. 464/11. At the time of sampling, the peripheral blood of the patient contained 82% blasts as assessed by cytomorphology. The blood sample was enriched for mononuclear cells through Ficoll-Hypaque and cryopreserved until use. Genomic DNA was extracted from the bulk samples using the AllPrep DNA/RNA Kit (Qiagen).
Sample preparation and single-cell printing
In principle, the SCP was used as described before . Prior to cell printing in the current study, the cells were re-suspended in PBS to yield a final concentration between 105 and 106 cells/ml. For each experiment, a new sterile cartridge with a 40 μm nozzle was filled with 30 μl sample and mounted on the SCP. The piezo stroke length was set to 10 μm and the downstroke velocity was set to 140 +/- 10 μm/s to achieve stable droplets. Individual cells were printed into the wells of a standard 384-microwell PCR plate. Electrostatic charges on the plates were neutralized with an ionizing air blower (minION2, SIMCO-ION, The Netherlands). Sample loading and instrument preparation took on average approximately 5 minutes.
Calculation of the dispenser offset
In order to compensate for dispenser offset, reference droplets were dispensed on a hydrophobic-coated glass slide that is imaged by a digital camera (DFM 72BUC02-ML, The Imaging Source, Germany) from below. The position of the droplet was then calculated from the image data by the SCP software using the.NET openCV wrapper Emgu CV. This fully automated process was carried out prior to the cell deposition and each time the offset was taken from the mean of three subsequently dispensed droplets. After completion of the single-cell deposition the dispenser offset was assessed again for comparison with the offset measured at the start of the experiment. By this means, a drift in the dispenser offset that could potentially occur during the experiment can be automatically detected. However, in this study, we experienced no significant drift that would compromise the precision of cell deposition into the microwells.
Metrics for the single-cell isolation performance
Single-cell isolation performance of the SCP was characterized using two measures. The ejection efficiency is defined as the number of single beads or cells ejected from the nozzle divided by the total number of printing events targeted to the microwell plate. The ejection efficiency is determined from the SCP images and is therefore independent of the target (e.g well). The deposition efficiency quantifies the number of single beads or cells correctly delivered to the bottom of the microwells. Since single fluorescent cells cannot always be clearly visualized on the microwell bottoms due to auto-fluorescence caused by the rough well surface, we used high-intensity fluorescent beads (Kisker Biotech, Germany) to determine the deposition efficiency.
Detection of nucleotide variants in the bulk specimens
Candidate gene mutations in the cell lines were selected via the COSMIC mutation database  and confirmed by Sanger sequencing (U-2 OS, Kasumi-1) or MiSeq-based targeted NGS (Kasumi-1) of bulk specimens. In the patient sample, variants were assessed by Sanger sequencing. Variant allele frequencies (VAFs) in Kasumi-1 were derived from NGS or pyrosequencing.
In the targeted NGS assay, 70 genes reported to be mutated in AML or other hematologic cancers were analyzed by multiplexed amplicon resequencing (Agilent HaloPlex); sequencing was performed on an Illumina MiSeq platform using 2 x 250 bp paired-end reads . Pyrosequencing was performed according to the manufacturer’s instruction using a PyroMark Q96 MD system.
CytoScan HD or Human SNP Array 6.0 arrays (Affymetrix) were performed on the bulk samples. The data were analyzed using the Chromosome Analysis Suite (ChAS) software. For the evaluation of copy number variations (CNVs), the normalized probe intensities for the A and B alleles were summarized to calculate allelic signal values. The allelic difference was calculated as the difference between the signal of the A allele minus B allele, and standardized so that an A allele genotype has a positive value and a B allele a negative value. The standardization was based on median values for the allelic difference under different genotype configurations determined by the reference set. The array data are deposited at http://www.ebi.ac.uk/arrayexpress/ (Acc. E-MTAB-4950). In addition, publically available SNP Array 6.0 data (NCBI GEO database acc. GSM879223) were used to identify heterozygous single nucleotide polymorphisms (SNPs) in U-2 OS (see below).
Whole-genome amplification of single-cell DNA
The printed cells were lysed and the DNA of each cell was amplified by WGA using the REPLI-g Single Cell Kit (Qiagen), which is based on multiple displacement amplification. The manufacturer’s protocol was modified in terms of a four-fold reduction of all reagents resulting in a final reaction volume of 12.5 μl. The DNA yield was assessed by Qubit fluorometric quantitation (Thermo Fisher Scientific) according to the manufacturer’s protocol. In addition, a multiplex PCR on repetitive LINE1 retrotransposons was used to evaluate the DNA after the WGA. This PCR generates specific products of different sizes irrespective of whether specific genomic regions were amplified better or worse by the WGA, and are thus over- or underrepresented. The LINE1 primers are provided in S1 Table.
For single-cell genotyping, the WGA DNA from the individual cells was subjected to PCR and Sanger sequencing of the selected variant loci. As WGA can lead to the preferential amplification of one allele and allelic dropout (ADO), we also sequenced SNPs that were identified by CNV array to be heterozygous in the bulk sample and located in close genomic proximity to the respective mutation loci. If, in a single cell, there was no mutated sequence at the mutation site and the respective SNP not heterozygous, then ADO may have occurred at the genomic locus, and the mutation analysis was deemed to be inconclusive. The primers are provided in S1 Table.
The SCP and its implementation into the single-cell genotyping workflow
The original SCP principle has been previously described in detail . Fig 1A–1C show the SCP prototype that we used for the present study and the workflow for single-cell isolation and analysis in the 384-well format: First, the cell suspension is pipetted into the disposable cartridge that consists of a milled plastic part and the microfluidic dispenser chip (Fig 1A). Next, the cartridge is mounted on the printhead that comprises the piezo actuator driving the dispenser chip (Fig 1B). A microscopic vision system monitors the nozzle of the dispenser chip and provides the image data for cell detection, classification and isolation (see below). Unwanted droplets are discarded via a vacuum shutter system. The printhead is mounted on a three-axis robotic stage which allows precise deposition of single-cell encapsulating droplets into microwells specified in the SCP software by the operator. Different from previous applications, in the present study, the SCP was used for the isolation of cancer cells and subsequent cell lysis, WGA and molecular genetic analyses (Fig 1D).
(A) The cell suspension is filled into the sterile single-use cartridge. (B) The microwell plate holder is equipped with a camera to automatically determine and adjust for the dispenser offset prior to cell printing (automatic offset compensation, AOC). The dispenser with the mounted cartridge and the cell detection optics are part of the printhead. (C) Total view of the SCP prototype that was used in this study. (D) Illustration of the workflow for single-cell genotyping. Individual cells are isolated via the SCP. After cell lysis, the DNA is subjected to whole genome amplification (WGA), which then can be used for routine molecular genetic analyses.
Evaluation of the precision and efficiency of single-cell deposition
A prerequisite for the genetic analyses is the exact deposition of the single cell in the well, since only then the cell lysis and WGA can be reliably performed, given the small reaction volumes.
Although the precision of the dispenser is sufficiently high to deposit single-cell encapsulating droplets into microwells, we observed that the droplet position within the well can vary. The reason is a variation of the nozzle position due to the cartridge fabrication process and the fixation of the cartridge to the printhead. In order to deposit droplets accurately onto the well bottom in an automated manner we designed a tool to compensate for such an offset by measuring the droplet placement position before and during the cell isolation process. For this, droplets are dispensed on a glass slide that is imaged by a digital camera attached to the microwell plateholder (Fig 2). The droplet position is extracted from the image data and the algorithm automatically calculates the correct dispensing position to target the center of the microwells.
(A) For this, droplets are dispensed on a glass slide that is imaged by a digital camera. (B) The actual droplet position is extracted from the image data by image processing with openCV. (C) displays the binary image after thresholding. The algorithm automatically calculates the correct dispensing position to target the center of the microwell.
In addition, free-flying droplets can be deflected by electrostatic forces, which occur due to the electric charge that accumulates on both the droplet and plate. Thus, we used ionized air to neutralize the electrostatic charging of the microwell plate.
In order to evaluate whether the SCP with the automatic dispense offset compensation and the deionization deposits single droplets with high efficiency and precision, single 10 μm sized green fluorescent latex beads as cell equivalents were printed into the wells of a 384-microwell plate, and the ejection and deposition efficiencies were assessed. The ejection efficiency (i.e. truly a single bead has been ejected from the nozzle) was determined through the images automatically stored by the SCP that show the nozzle before, during, and after the dispensation (Fig 3A–3E). The deposition efficiency (i.e. a single bead was successfully delivered to the bottom of the well) was concluded from fluorescence microscopy images (Fig 3F).
Four consecutive images are stored automatically for each printing event: (A-C) A cell (or bead as cell equivalent) is transported towards the nozzle of the dispenser-chip, where it is detected and classified within a region of interest (ROI, green area). Only if the object recognition meets predefined criteria in terms of size, roundness and singularity, the droplet ejected from the nozzle will be targeted to the well. (D) A final image confirms the absence of the cell in the nozzle after droplet ejection. The image series can be used to provide direct evidence that truly a single cell was ejected. (E) shows an example for an image where two cells would enter the droplet. Such droplets are automatically discarded by the vacuum suction. To evaluate the precision of the instrument, 2304 single fluorescent beads were printed into six 384-microwell plates. The images were evaluated to determine the ejection efficiency (99.7%). (F) Correctly deposited beads (dashed circle) were visualized by fluorescence microscopy of the well bottoms (1.2 mm in diameter). (G) The beads were correctly delivered in an average of 98.8% of the wells if the microwell plate was electrostatically neutralized before printing.
Of the fluorescent beads, 1152 each were dispensed into three untreated or three deionized 384-well plates; this equaled a total number of 2304 beads. The overall single-bead ejection efficiency was on average 99.7 ± 0.3%. The deposition efficiency depended on whether the plate was deionized or not. Without prior deionization, in only 20.7 ± 8.4% of the well bottoms a single bead was detected, while after deionization 98.8 ± 1.5% of the beads were correctly delivered (Fig 3G).
Following this workflow, a total of 150 single cells of different origins (U-2 OS, n = 40; Kasumi-1, n = 44; AML patient, n = 66) were printed into deionized 384-well plates resulting in a total single-cell ejection efficiency of 98.7%. A subset of the printed cells of each specimen was subjected to WGA and genotyping (as detailed below).
Whole genome amplification of single-cells
Single cells were subjected to WGA prior to downstream molecular analysis. In order to minimize the odds for contaminating DNA that would be co-amplified by the WGA, we worked with DNA-free cartridges and plates and reduced the hands-on steps during cell isolation, lysis and amplification. The success of the WGA was assessed by fluorometric quantitation of the DNA, and a PCR on repetitive LINE1 transposons was used to control for the amplification of human DNA in the samples and its absence in the no-template control.
Of the 40 U-2 OS cells that were deposited into the deionized microwells, 25 were subjected to a WGA resulting in a median DNA yield of 3.8 μg (range, 3.5–5.5 μg) per cell (Fig 4A); the PCR on the LINE1 transposons was positive in all samples (Fig 4B). Of Kasumi-1, 33 cells were subjected to WGA, resulting in a median DNA yield of 14.3 μg (range, 8.6–20.8 μg) per cell, and the LINE1 PCR was positive in all cells (S1 Fig). Among the 23 single cells from an AML patient, the WGA resulted in a median DNA yield of 16.3 μg (range, 14.0–19.3 μg) per cell and a positive LINE1 PCR in all cells (S2 Fig).
(A) Bar diagram displaying the WGA DNA yields from the individual U-2 OS cells and the respective controls, as measured by Qubit™. (B) Agarose gel illustrating the differently sized products of the LINE1 multiplex PCR that was performed on the WGA DNA of the individual U-2 OS cells. (C) Exemplary sequencing chromatograms of the SLC34A2 and TET2 gene mutations in the cell bulk and individual cells. (D) Conclusions on the occurrence of allelic dropout (ADO) through sequencing of single nucleotide polymorphisms (SNPs). SNPs rs1391438 and rs7655890 are located in close genomic proximity to the TET2 mutation and show heterozygous patterns in the cell bulk (left). In the single U-2 OS cells B8 and C10, wild-type only is detected at the TET2 mutation site. The heterozygous patterns of the SNPs in B8 suggest true wild-type in TET2, while the detection of only one allele of both SNPs in C10 suggest loss of the genomic region due to ADO. NTC: no-template control, PTC: positive control.
We also examined whether free-floating DNA was present in the droplets generated by the SCP. Such DNA, if amplified by the WGA, would hinder the genetic analyses of the single cells. Therefore, empty droplets (n = 1, 3, and 10, respectively) from a suspension of Kasumi-1 cells were printed into individual wells of a 384-well plate and then subjected to WGA. All empty droplets yielded no product in the subsequent LINE1 PCR, while droplets containing single Kasumi-1 cells were positive (S3 Fig).
Genotyping of single cancer cells
We sought to evaluate the applicability of the SCP for the isolation and genetic analyses of single cancer cells. For this, we studied representative gene variants in U-2 OS, Kasumi-1 and the PBMCs of a patient with AML.
U-2 OS harbors mutations in the SLC34A2 (ENST00000382051: c.1538G>T; p.R513L) and TET2 genes (ENST00000380013: c.1394C>T; p.P465L) , both of which are of functional relevance in cancers [19–21]. We confirmed the mutations in SLC34A2 and TET2 in the bulk sample. In line with published data , the chromatograms suggested that the SLC34A2 mutation was homo- or hemizygous and the TET2 mutation heterozygous. From our CNV array data, we concluded that the zygosity of the SLC34A2 mutation was due to the loss of heterozygosity (LOH) of the respective genomic region. In the 25 U-2 OS cells analyzed, the SLC34A2 mutation was detected in 23 and the TET2 mutation in 19 cells (Figs 4C and 5A). In one cell, the SLC34A2 PCR and, in another cell, both the SLC34A2 and TET2 PCR repeatedly failed, which suggests insufficient amplification of the target region by the WGA. As expected from the zygosity in the bulk, no cell with SLC34A2 wild-type sequence was detected. In contrast, TET2 wild-type sequence only was detected in 5 cells. These cells were evaluated for the presence of ADO to allow conclusions regarding the co-occurrence of mutations in the individual cells (see below).
(A) U-2 OS cell line, (B) Kasumi-1 cell line and (C) AML patient. Displayed are the nucleotides identified by sequencing of the bulk specimens and the individual cells (annotated for example B1 or C1). Highlighted in red is the presence and in green the absence of the respective mutated sequence. Highlighted in grey are inconclusive analyses either due to failed PCR (n.d., not determined) or the likely occurrence of allelic dropout (*). For the gene mutation analyses, the clonal architecture concluded from the single-cell analyses is schematically displayed.
Kasumi-1 harbors mutations in the tyrosine kinase KIT (ENST00000288135: c.2466T>A; p.N822K) and the tumor suppressor TP53 (ENST00000269305: c.743G>A; p.R248Q) . The mutations in KIT and TP53 were confirmed by NGS in a Kasumi-1 bulk sample. As verified by pyrosequencing, the VAF of the KIT mutation was 84.0% at median (range, 83.3–85.2%). The overrepresentation of the mutated allele is due to the amplification of the KIT genomic region [22,23]. The TP53 mutation was present with a VAF of 100% in line with an LOH of the chromosome 17p region in the CNV array. The KIT mutation was detected in 30 and the TP53 mutation in 25 cells (Fig 5B). In the remaining cells, the KIT or TP53 PCR failed, most likely due to an inefficient amplification of the respective regions by the WGA. No cell with KIT or TP53 wild-type sequence only was detected. With regard to the co-occurrence of the mutations, the analyses yielded informative results for both mutations in 23 cells. All these cells harbored both the KIT and TP53 mutation (Fig 5B).
In the PBMCs of a patient with AML, we assessed the potentially pathogenic non-synonymous SNP rs1042522 in TP53 (ENST00000269305: c.215C>G; p.P72R) [24,25]. We decided for this approach since no C-allele was detectable by Sanger sequencing of the bulk specimen and since, as indicated by FISH and CNV array, the AML harbored one or more clones with loss of a chromosome 17p allele (including TP53; S4 Fig), and chromosomal loss of TP53 in cancers preferentially affects the C-allele of rs1042522 . Thus, we tested whether an ancestral C-allele would be still detectable in a subset of individual cells. Indeed, the TP53 PCR yielded a product in 21 cells, in 5 of which the C-allele was detected (Fig 5C).
Evaluation of allelic dropout and co-occurrence of mutations in U-2 OS
As stated above, in 5 U-2 OS cells the TET2 wild-type sequence only was detected. To evaluate whether the absence of TET2 mutations in these cells was due to ADO, we analyzed the SNPs rs1391438 and rs7655890 (located 4,650 bp and 15,992 bp 5’ from the TET2 mutation, respectively) in these cells; both SNPs were heterozygous in the bulk sample (Fig 4C). In one of the 5 cells, only one of the two alleles of each SNP was detected, which strongly suggests that ADO has occurred at the genomic region that included the SNPs and TET2 mutation (Fig 4C). Thus, we deemed the analysis of this one cell inconclusive. In the remaining 4 cells, both of the SNPs were heterozygous, suggesting that WGA has successfully amplified both alleles (Fig 4C); this makes it unlikely that the absence of the TET2 mutation in these cells was due to ADO. Thus, we concluded that these 4 cells indeed lacked the TET2 mutation.
Thus, in terms of co-occurrence, our analyses yielded informative results for both mutation sites in 22 cells. Of these, 18 cells harbored both the SLC34A2 and TET2 mutation while 4 harbored the SLC34A2 but not the TET2 mutation, which indicates clonal heterogeneity with regard to TET2 mutated cells within the U-2 OS cell line (Fig 5A).
In Kasumi-1, no evaluation of ADO was necessary since no cell with KIT or TP53 wild-type sequence only was detected.
Single-cell analyses are the gold standard for deciphering the genetic clonal architecture of solid and blood cancers. Yet, current techniques most often assess gene mutations in the entire population of malignant cells without taking into account that cells might differ genetically from each other. Here, we assessed gene mutations and polymorphisms in bulk samples and individual cancer cells, which were isolated using an improved version of the SCP.
We previously demonstrated that the SCP allows for the isolation and deposition of individual cells with minor impact on cell integrity . The sterile single-use cartridges can be operated with sample volumes as low as 5 μl, have a minimal dead volume, and avoid cross-contamination, as they are the only part that is in contact with the sample. Moreover, the image data that the SCP collects and stores during each experiment, allows for verification that truly a single cell was ejected from the nozzle. Potential double-cell events (which did not occur during this study) can be therefore excluded from downstream analysis without additional imaging of the microwells. The images can be also used for interrogating basic morphological properties such as size and roundness of the printed cell. In summary, the SCP provides the required premises to isolate individual cells from even precious samples for subsequent molecular analyses.
In order to allow accurate cell deposition, for the present study, we improved our established SCP by an automated dispense position measurement system which ensures that the droplets are accurately dispensed onto the specified target positions without any additional user interaction. The system also allows monitoring whether the dispenser delivers stable droplets throughout the cell isolation process. This is a benefit compared to FACS devices, where manual fine-tuning prior to cell isolation is required, including definition of the sorting parameters (fluorescence intensity, forward and side scatter) or alignment of the plate-sorting unit to the microwells.
The single-cell containing droplets that are ejected from the SCP are 160 pl in volume and have velocities of typically 2 m/s. In case of spontaneous electrostatic droplet charging , such droplets can be deflected by electrostatic forces due to interaction with the substrate (i.e. the microwell plate). In order to avoid such deflection the droplets or substrate need to be free of electrostatic charge. Here, we successfully applied ionized air to neutralize the charging on the plate. This resulted in droplet trajectories without significant deflection, which was verified by the precise deposition of fluorescent beads onto the bottom of the microwells yielding a deposition efficiency of 98.8%. This is significantly higher than the single-cell trapping efficiencies that are frequently achieved with hydrodynamic cell trapping in microfluidic chips .
In the current study, we used the SCP for the isolation of individual cells of cancer cell lines and a patient AML sample to study gene variants that we had detected in the respective bulk specimens. For this, a total of 81 of the printed cells were subjected to WGA to generate sufficient DNA for the genetic analyses. The WGA was successful in all cells, and the DNA yields were uniform and high across the cells isolated per SCP run. In addition, the four-fold reduction of WGA reagents, that we applied in our protocol, implied a profound reduction in costs.
The single-cell containing droplets that are ejected from the SCP are very small, as mentioned above; they are approximately 20x less in volume than the droplets typically produced by FACS. This minimizes the possibility of free-floating DNA in the medium that surrounds the single cell. We nevertheless evaluated the presence of free-floating human DNA in the droplets by printing empty droplets (i.e. not containing a cell, as verified by the SCP image data) from a cell suspension and subjecting these droplets to WGA. While the LINE1 PCR yielded products for the cell-containing droplets, it remained negative for all empty droplets. This indicates that free-floating human DNA in the droplets is, if at all, a rare event, which clearly improves the reliability of the single-cell data gained from SCP experiments.
An issue of WGA on single-cell DNA is the potential occurrence of ADO. This is of minor importance if the wild-type allele is not amplified, since the mutation will still be detectable. However, if the mutated allele is affected, then this can lead to false interpretation of a cell as being wild-type in the respective gene. In order to control for ADO of the mutated allele, we analyzed cases with the detection of wild-type only for SNPs that were heterozygous in the bulk specimen and located in genomic proximity to the mutation site. If the SNPs were not heterozygous (i.e. lost one allele) in the single cell, then the mutated allele was deemed to be lost by ADO. In U-2 OS, TET2 wild-type only was identified in 5 cells. Based on the SNP analyses we concluded that 4 of the 5 cells indeed did not harbor the TET2 mutation (as both alleles of the SNPs were detected), while in one cell the TET2 mutated allele may have been lost due to ADO (as only one allele of the SNPs was detected). This implies that SNP and mutation sites are present in the same WGA fragments. This is the more probable the closer the sites are located to each other; ideally, they are covered by same PCR amplicon, which is rarely possible. However, WGA fragments have an average product length of more than 10kb [9, 27]. Thus, despite the residual uncertainty, the SNPs that we used were likely suitable to control for ADO of the TET2 mutation site.
The analyses of the overall 81 single cells yielded 133 successful sequencing reactions and allowed insights into the clonal genetic architecture of the samples.
Among the 22 U-2 OS cells with results for both the SLC34A2 and TET2 mutation, 18 cells harbored both mutations and 4 harbored the SLC34A2 but not the TET2 mutation. This indicates that U-2 OS consists of clones that are heterogeneous with regard to the TET2 mutation status. Our findings are in line with the absence of SLC34A2 wild-type but presence of both TET2 wild-type and mutated sequences in the bulk sample.
In the 33 Kasumi-1 cells, the TP53 PCR failed in 8 cells, likely since the respective region on chromosome 17p did not amplify during the WGA, despite the overall success of the WGA in these cells. The amplification failure of the TP53 region may be attributable to the LOH of the 17p arm in Kasumi-1, since in this case only one allelic copy (as opposed to two in a diploid cell) serves as template for the WGA. Of the 23 cells with information on both KIT and TP53, all cells harbored both mutations.
Among the 23 single cells of the AML patient, the analysis of the TP53 polymorphism was successful in 21 cells. In the bulk sample, the cytogenetic data indicated the loss of one copy of the TP53 encoding chromosomal region, and no C-allele was detectable by Sanger sequencing. Based on this and considering the poor sensitivity of Sanger sequencing, the ancestral genotype in the TP53 SNP may have been G/G or G/C. From the analyses we concluded that the ancestral genotype was G/C and that the C-allele was affected by the chromosomal deletion. This is in line with the observation that chromosomal loss of TP53 preferentially affects the C-allele [25,28].
In addition to previous reports by us and others [6–9] we here display examples on how information at the single-cell level can complement and extend the genetic information derived from bulk specimens. The single-cell genotyping allowed verifying the co-occurrence of variants in a given cell, which is essential since only variants that co-exist in a cell can indeed impact together on the biology of this cell. Moreover, the verification or falsification of the co-occurrence of variants allowed conclusions regarding the clonal architecture and evolution.
We are aware that our study has limitations. The number of cancer samples, cells per sample and mutations per cell that we analyzed is relatively small; the analyses of more cells and mutations would allow a more profound insight into the possibilities and limitations of our technique as well as into the clonal architecture of the samples.
However, our study for the first time demonstrates how the SCP, that we had previously established and the precision of which we have further improved for the present study, is used to isolate individual cancer cells in a highly automated manner for molecular genetic analyses. Of particular significance is that, on the cells isolated with the SCP, we obtained uniform and high DNA amounts through WGA and applied routine downstream gene analyses. These features of the SCP and the prior identification of candidate variants in bulk specimens, which then can be studied for co-occurrence in relatively few cells, also demonstrate how meaningful results are obtained from single-cell genotyping at relatively low costs. The costs are indeed further lowered as one SCP cartridge can be used for the isolation of any number of cells per sample. Although not yet routinely performed the clinical demand for single-cell genotyping, as performed in our study, will likely increase, together with the use of NGS and targeted therapies, and the accordingly increased focus on clonal architecture and evolution of cancer.
In conclusion, we present an efficient workflow for the genetic analysis of individual cancer cells using the SCP for automated cell isolation. Given the flexibility of the SCP and its improved precision in cell deposition we were able to reliably use the instrument in combination with routine downstream genetic applications. In the future, we will combine the SCP with robotic liquid handling for further assay automation, corroborate our workflow for use with biopsies and explore the application of our workflow for NGS and the concurrent analyses of genetic and epigenetic aberrations.
S1 Fig. Whole genome amplification and PCR on single Kasumi-1 cells.
S2 Fig. Whole genome amplification and PCR on single AML patient cells.
S3 Fig. Whole genome amplification and PCR on empty droplets.
S4 Fig. Allele peak plot of chromosome arm 17p in the AML patient.
We would like to thank Gabriele Greve, Nadja Blagitko-Dorfs and Tobias Ma for their methodological support, and Milena Pantic for the fluorescence in situ hybridization.
- Conceptualization: JR NR CN ML JD PK RZ RC SZ HB.
- Data curation: JR NR CN DP KHM SZ HB.
- Formal analysis: DP KHM RC.
- Funding acquisition: KHM RC PK HB.
- Investigation: JR NR CN DP JMS KHM BH RC SZ HB.
- Methodology: JR NR CN DP KHM BH RC SZ HB.
- Project administration: SZ HB.
- Resources: DP KHM BH ML JD RZ RC.
- Software: JR DP KHM RC.
- Supervision: PK RZ SZ HB.
- Validation: JR NR CN SB JMS KHM.
- Visualization: JR NR CN SB DP JMS SZ HB.
- Writing – original draft: JR SZ HB.
- Writing – review & editing: JR NR CN SB DP JMS KHM BH ML JD PK RZ RC SZ HB.
- 1. Wakita S, Yamaguchi H, Ueki T, Usuki K, Kurosawa S, Kobayashi Y, et al. Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. Leukemia 2015;30:1–10.
- 2. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013;501:355–364. pmid:24048068
- 3. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014;512:1–15.
- 4. Yu C, Yu J, Yao X, Wu WK, Lu Y, Tang S, et al. Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. Cell Res 2014;24:701–712. pmid:24699064
- 5. Gawad C, Koh W, Quake SR. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc Natl Acad Sci U S A 2014;111:17947–17952. pmid:25425670
- 6. Hughes AEO, Magrini V, Demeter R, Miller CA, Fulton R, Fulton LL, et al. Clonal Architecture of Secondary Acute Myeloid Leukemia Defined by Single-Cell Sequencing. PLoS Genet 2014;10:e1004462. pmid:25010716
- 7. Klco JM, Spencer DH, Miller C a., Griffith M, Lamprecht TL, O’Laughlin M, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014;25:379–392. pmid:24613412
- 8. Paguirigan AL, Smith J, Meshinchi S, Carroll M, Maley C, Radich JP. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci Transl Med 2015;7:1–10.
- 9. Niemöller C, Renz N, Bleul S, Blagitko-Dorfs N, Greil C, Yoshida K, et al. Single cell genotyping of exome sequencing-identified mutations to characterize the clonal composition and evolution of inv(16) AML in a CBL mutated clonal hematopoiesis. Leuk Res 2016;47:41–46. pmid:27244256
- 10. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90–94. pmid:21399628
- 11. Gross A, Schoendube J, Zimmermann S, Steeb M. Technologies for Single-Cell Isolation. Int J Mol Sci 2015;16:16897–919. pmid:26213926
- 12. Navin NE. Cancer genomics: one cell at a time. Genome Biol 2014;15:452. pmid:25222669
- 13. Jaitin DA, Kenigsberg E, Keren-Shaul H, Elefant N, Paul F, Zaretsky I, et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 2014;343:776–779. pmid:24531970
- 14. Szulwach KE, Chen P, Wang X, Wang J, Weaver LS, Gonzales ML, et al. Single-Cell Genetic Analysis Using Automated Microfluidics to Resolve Somatic Mosaicism. PLoS One 2015;10:e0135007. pmid:26302375
- 15. Gross A, Schondube J, Niekrawitz S, Streule W, Riegger L, Zengerle R, et al. Single-Cell Printer: Automated, On Demand, and Label Free. J Lab Autom 2013;18:504–518. pmid:24222537
- 16. Stumpf F, Schoendube J, Gross a., Rath C, Niekrawietz S, Koltay P, et al. Single-cell PCR of genomic DNA enabled by automated single-cell printing for cell isolation. Biosens Bioelectron 2015;69:301–306. pmid:25771302
- 17. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: Exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015;43:D805–811. pmid:25355519
- 18. Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Goerlich D, et al Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016 Jun 10. pii: blood-2016-01-693879. [Epub ahead of print]
- 19. Lin K, Rubinfeld B, Zhang C, Firestein R, Harstad E, Roth L, et al. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers. Clin Cancer Res 2015;21:5139–51351. pmid:26156394
- 20. Ge G, Zhou C, Ren Y, Tang X, Wang K, Zhang W, et al. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling. Tumor Biol 2015;37:5049–5062.
- 21. Langemeijer S, Kuiper R, Berends M, Knops R, Aslanyan M, Massop M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41:838–842. pmid:19483684
- 22. Becker H, Pfeifer D, Afonso JD, Nimer SD, Veelken H, Schwabe M, et al. Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the “second hit” hypothesis. Leukemia 2008;22:1792–1794. pmid:18385756
- 23. Beghini A, Magnani I, Ripamonti CB, Larizza L. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. HematolJ 2002;3:157–163.
- 24. Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, et al. Mutations and polymorphisms in TP53 gene—An overview on the role in colorectal cancer. Mutagenesis 2012;27:211–218. pmid:22294769
- 25. Dahabreh IJ, Schmid CH, Lau J, Varvarigou V, Murray S, Trikalinos TA. Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: A systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J Epidemiol 2013;177:1317–1325. pmid:23729685
- 26. Choi D, Lee H, Im DJ, Kang IS, Lim G, Kim DS, et al. Spontaneous electrical charging of droplets by conventional pipetting. Sci Rep 2013;3:2037. pmid:23784001
- 27. Dean FB, Hosono S, Fang L, Wu X, Faruqi AF, Bray-Ward P, et al. Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci U S A. 2002;99:5261–5266. pmid:11959976
- 28. Dumont P, Leu JI-J, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357–365. pmid:12567188